Current Keytruda Clinical Trial Locations: A Comprehensive Overview

What is Keytruda?

Keytruda, also known as pembrolizumab, is a medication used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and classical Hodgkin lymphoma. Developed by Merck & Co., Inc., Keytruda is a programmed death receptor-1 (PD-1) inhibitor, which works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating the immune system to attack cancer cells.

Current Keytruda Clinical Trials

As of 2023, Keytruda is being investigated in numerous clinical trials across the globe. These trials aim to evaluate the safety and efficacy of Keytruda in various cancer types, including:

Melanoma

* KEYNOTE-716: A phase III trial evaluating Keytruda in combination with ipilimumab in patients with unresectable or metastatic melanoma (NCT03146829)
* KEYNOTE-604: A phase III trial comparing Keytruda to dacarbazine in patients with unresectable or metastatic melanoma (NCT02460198)

Lung Cancer

* KEYNOTE-189: A phase III trial evaluating Keytruda in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) (NCT02422587)
* KEYNOTE-042: A phase III trial comparing Keytruda to chemotherapy in patients with metastatic NSCLC (NCT02409342)

Kidney Cancer

* KEYNOTE-426: A phase III trial evaluating Keytruda in combination with axitinib in patients with advanced renal cell carcinoma (RCC) (NCT02921649)
* KEYNOTE-564: A phase III trial comparing Keytruda to sunitinib in patients with advanced RCC (NCT03132245)

Classical Hodgkin Lymphoma

* KEYNOTE-204: A phase II trial evaluating Keytruda in patients with relapsed or refractory classical Hodgkin lymphoma (NCT02493459)
* KEYNOTE-087: A phase II trial comparing Keytruda to brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma (NCT01953637)

Clinical Trial Locations

Keytruda clinical trials are being conducted at various locations worldwide. According to DrugPatentWatch.com, as of 2023, Keytruda clinical trials are being conducted in:

* United States: Over 300 clinical trial sites across the country, including major cities like New York, Los Angeles, Chicago, and Houston.
* Europe: Over 150 clinical trial sites across the continent, including major cities like London, Paris, Berlin, and Rome.
* Asia-Pacific: Over 100 clinical trial sites across the region, including major cities like Tokyo, Seoul, Hong Kong, and Singapore.
* Latin America: Over 50 clinical trial sites across the region, including major cities like Mexico City, São Paulo, and Buenos Aires.

Conclusion

Keytruda is a promising immunotherapy agent being investigated in numerous clinical trials worldwide. As a patient, it is essential to consult with a healthcare professional to determine if you are eligible to participate in a Keytruda clinical trial. Remember to carefully review the trial's inclusion and exclusion criteria, as well as the potential risks and benefits associated with participation.

Key Takeaways

* Keytruda is a PD-1 inhibitor being investigated in various cancer types, including melanoma, lung cancer, kidney cancer, and classical Hodgkin lymphoma.
* Keytruda clinical trials are being conducted at numerous locations worldwide, including the United States, Europe, Asia-Pacific, and Latin America.
* Patients should consult with a healthcare professional to determine eligibility for Keytruda clinical trials.
* Carefully review trial inclusion and exclusion criteria, as well as potential risks and benefits associated with participation.

Frequently Asked Questions

1. What is Keytruda used to treat?
Keytruda is used to treat various types of cancer, including melanoma, lung cancer, kidney cancer, and classical Hodgkin lymphoma.
2. How does Keytruda work?
Keytruda works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating the immune system to attack cancer cells.
3. What are the current Keytruda clinical trial locations?
Keytruda clinical trials are being conducted in the United States, Europe, Asia-Pacific, and Latin America.
4. How do I find out if I'm eligible for a Keytruda clinical trial?
Patients should consult with a healthcare professional to determine eligibility for Keytruda clinical trials.
5. What are the potential risks and benefits associated with participating in a Keytruda clinical trial?
Patients should carefully review the trial's inclusion and exclusion criteria, as well as the potential risks and benefits associated with participation.

Sources

1. Merck & Co., Inc. (2023). Keytruda (pembrolizumab) Prescribing Information.
2. DrugPatentWatch.com. (2023). Keytruda Clinical Trials.
3. National Cancer Institute. (2023). Pembrolizumab (Keytruda).
4. ClinicalTrials.gov. (2023). Keytruda Clinical Trials.
5. American Cancer Society. (2023). Keytruda (Pembrolizumab).